Altimmune, Inc. today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences.
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences:
- BTIG Obesity Health Forum (Virtual Conference)
Title: Emerging Therapeutics Panel
Wednesday, May 8, 2024
Panel Discussion at 4:00 pm Eastern Time
- GLP-1-Based Therapeutics Summit (Philadelphia, PA)
- Title: Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver Disease
Wednesday, May 15, 2024
Presentation at 10:00 am Eastern Time
- Title: Attaining Product Differentiation through Improved Patient Segmentation & Efficiency
Thursday, May 16, 2024
Presentation at 1:30pm Eastern Time
- Title: Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver Disease
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
